Disease & Vaccine Information

Please select disease or vaccine
Ask 8 Information Kiosk

Explore FREE downloadable educational materials.

Connect with us!

Report Your Vaccine Experiences

Read and report vaccine reactions, harassment and failures. 

Who should not get Respiratory Syncytial Virus (RSV) Vaccine?

Updated August 25, 2023


According to the package insert for both GSK’s AREXVY  and Pfizer’s ABRYSVO  RSV vaccine, anyone with a history of severe allergic reaction to any of the ingredients contained in the vaccine should not receive a dose of vaccine.

On July 17, 2023, the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV in infants and children up to 24 months of age. Though the CDC has determined that it can define nirsevimab as a vaccine for their purposes, nirsevimab is not classified as a vaccine by the FDA, American Medical Association or the World Health Organization.         To learn about nirsevimab, visit NVIC’s RSV Prevention and Treatment page.

IMPORTANT NOTE: NVIC encourages you to become fully informed about Respiratory Syncytial Virus (RSV) and the Respiratory Syncytial Virus (RSV) vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
Opens in new tab, window
Opens an external site
Opens an external site in new tab, window